GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Vaccine Biologics Corp (ROCO:6547) » Definitions » EBIT

Medigen Vaccine Biologics (ROCO:6547) EBIT : NT$-61.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medigen Vaccine Biologics EBIT?

Medigen Vaccine Biologics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was NT$-20.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-61.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medigen Vaccine Biologics's annualized ROC % for the quarter that ended in Dec. 2024 was -7.72%. Medigen Vaccine Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -4.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medigen Vaccine Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -0.43%.


Medigen Vaccine Biologics EBIT Historical Data

The historical data trend for Medigen Vaccine Biologics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Vaccine Biologics EBIT Chart

Medigen Vaccine Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -657.86 1,416.28 -1,447.69 -1,122.26 -61.58

Medigen Vaccine Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -572.71 -64.02 18.78 3.64 -19.98

Competitive Comparison of Medigen Vaccine Biologics's EBIT

For the Biotechnology subindustry, Medigen Vaccine Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's EV-to-EBIT falls into.


;
;

Medigen Vaccine Biologics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-61.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Vaccine Biologics  (ROCO:6547) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medigen Vaccine Biologics's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-179.804 * ( 1 - 0% )/( (2385.597 + 2273.783)/ 2 )
=-179.804/2329.69
=-7.72 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4315.984 - 164.888 - ( 1765.499 - max(0, 199.891 - 2536.087+1765.499))
=2385.597

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4363.906 - 174.51 - ( 1915.613 - max(0, 214.218 - 2556.914+1915.613))
=2273.783

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medigen Vaccine Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-79.932/( ( (1328.732 + max(519.645, 0)) + (1353.554 + max(456.367, 0)) )/ 2 )
=-79.932/( ( 1848.377 + 1809.921 )/ 2 )
=-79.932/1829.149
=-4.37 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(183.699 + 433.38 + 67.871) - (164.888 + 0 + 0.417)
=519.645

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(118.032 + 452.062 + 61.229) - (174.51 + 0 + 0.446)
=456.367

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medigen Vaccine Biologics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-61.575/14317.639
=-0.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Vaccine Biologics EBIT Related Terms

Thank you for viewing the detailed overview of Medigen Vaccine Biologics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Vaccine Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Neihu Road, Lane 120, Floor 7, Section 1, Neihu District, Taipei, TWN, 11493
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Medigen Vaccine Biologics Headlines

No Headlines